Macquarie Group LTD Sarepta Therapeutics, Inc. Transaction History

Macquarie Group LTD

  • $90.3 Billion
  • Q3 2024

A detailed history of Macquarie Group LTD transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 38,910 shares of SRPT stock, worth $4.63 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
38,910
Previous 36,591 6.34%
Holding current value
$4.63 Million
Previous $5.78 Million 15.95%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$124.33 - $156.75 $288,321 - $363,503
2,319 Added 6.34%
38,910 $4.86 Million
Q2 2024

Aug 09, 2024
BUY
$113.33 - $163.85 $1.4 Million - $2.03 Million
12,393 Added 51.21%
36,591 $5.78 Million
Q1 2024

May 14, 2024
SELL
$93.7 - $141.53 $160,976 - $243,148
-1,718 Reduced 6.63%
24,198 $3.13 Million
Q4 2023

Feb 14, 2024
BUY
$67.31 - $124.76 $145,120 - $268,982
2,156 Added 9.07%
25,916 $2.5 Million
Q3 2023

Nov 14, 2023
BUY
$102.5 - $123.59 $202,130 - $243,719
1,972 Added 9.05%
23,760 $2.88 Million
Q2 2023

Aug 14, 2023
SELL
$106.4 - $157.19 $461,350 - $681,575
-4,336 Reduced 16.6%
21,788 $2.5 Million
Q1 2023

May 15, 2023
BUY
$117.53 - $155.99 $61,350 - $81,426
522 Added 2.04%
26,124 $3.6 Million
Q4 2022

Feb 21, 2023
SELL
$100.86 - $132.13 $694,521 - $909,847
-6,886 Reduced 21.2%
25,602 $3.32 Million
Q3 2022

Nov 14, 2022
SELL
$75.71 - $119.24 $391,572 - $616,709
-5,172 Reduced 13.73%
32,488 $3.7 Million
Q2 2022

Aug 15, 2022
BUY
$62.69 - $88.44 $14,794 - $20,871
236 Added 0.63%
37,660 $2.82 Million
Q1 2022

May 16, 2022
BUY
$63.15 - $90.42 $1.39 Million - $1.99 Million
22,046 Added 143.36%
37,424 $2.92 Million
Q4 2021

Feb 11, 2022
BUY
$77.28 - $99.42 $40,958 - $52,692
530 Added 3.57%
15,378 $1.39 Million
Q3 2021

Nov 12, 2021
SELL
$65.97 - $92.48 $10.8 Million - $15.1 Million
-163,720 Reduced 91.68%
14,848 $1.37 Million
Q2 2021

Aug 13, 2021
BUY
$69.38 - $86.75 $11.4 Million - $14.3 Million
164,586 Added 1177.13%
178,568 $13.9 Million
Q1 2021

May 14, 2021
SELL
$72.25 - $168.95 $45.3 Million - $106 Million
-627,300 Reduced 97.82%
13,982 $1.04 Million
Q4 2020

Feb 16, 2021
BUY
$125.56 - $178.74 $12.3 Million - $17.6 Million
98,220 Added 18.09%
641,282 $109 Million
Q3 2020

Nov 13, 2020
BUY
$127.12 - $172.34 $1.79 Million - $2.43 Million
14,075 Added 2.66%
543,062 $76.3 Million
Q2 2020

Aug 11, 2020
BUY
$93.0 - $171.7 $47 Million - $86.7 Million
505,065 Added 2111.3%
528,987 $84.8 Million
Q4 2019

Feb 14, 2020
BUY
$76.53 - $135.58 $70,560 - $125,004
922 Added 4.01%
23,922 $3.09 Million
Q3 2019

Nov 14, 2019
SELL
$72.81 - $156.91 $24.9 Million - $53.6 Million
-341,424 Reduced 93.69%
23,000 $1.73 Million
Q2 2019

Aug 14, 2019
BUY
$112.21 - $151.95 $1.61 Million - $2.18 Million
14,327 Added 4.09%
364,424 $55.4 Million
Q1 2019

May 15, 2019
SELL
$106.67 - $151.68 $15.7 Million - $22.3 Million
-146,769 Reduced 29.54%
350,097 $41.7 Million
Q4 2018

Feb 15, 2019
SELL
$97.32 - $148.76 $1.76 Million - $2.69 Million
-18,086 Reduced 3.51%
496,866 $54.2 Million
Q3 2018

Nov 15, 2018
BUY
$115.31 - $161.51 $15.2 Million - $21.3 Million
131,859 Added 34.42%
514,952 $83.2 Million
Q2 2018

Aug 14, 2018
BUY
$71.74 - $153.69 $22.4 Million - $48.1 Million
312,670 Added 443.99%
383,093 $50.6 Million
Q1 2018

May 11, 2018
BUY
$54.02 - $82.27 $2.56 Million - $3.9 Million
47,423 Added 206.19%
70,423 $5.22 Million
Q4 2017

Feb 15, 2018
SELL
$47.64 - $56.75 $476,400 - $567,500
-10,000 Reduced 30.3%
23,000 $1.28 Million
Q3 2017

Nov 08, 2017
BUY
$35.73 - $47.15 $1.18 Million - $1.56 Million
33,000
33,000 $1.5 Million

Others Institutions Holding SRPT

# of Institutions
529
Shares Held
84.2M
Call Options Held
2.06M
Put Options Held
1.52M
View Full List

About Sarepta Therapeutics, Inc.

SRPT Quotes by TradingView
  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email